Coeptis Therapeutics company info

What does Coeptis Therapeutics do?
Coeptis Therapeutics (NASDAQ:COEP) is a dynamic biotechnology firm dedicated to developing innovative treatments aimed at addressing unmet medical needs in various therapeutic areas. The company is traded exclusively on the NASDAQ stock exchange under the ticker code (NASDAQ:COEP), highlighting its focus on delivering cutting-edge healthcare solutions. Coeptis Therapeutics engages in a range of projects, from early-stage research to advanced clinical trials, aiming to pioneer new treatments that can dramatically improve patient outcomes. With a commitment to excellence and innovation, the company's primary objectives include advancing its current drug development programs, securing strategic partnerships, and expanding its pipeline with high potential therapeutic candidates. Through these efforts, Coeptis Therapeutics strives to make a significant impact in the medical field, bringing hope and new opportunities to patients around the globe.
Coeptis Therapeutics company media
Company Snapshot

Is Coeptis Therapeutics a public or private company?

key
Ownership
Public

How many people does Coeptis Therapeutics employ?

people
Employees
6

What sector is Coeptis Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Coeptis Therapeutics?

location pin
Head Office
Pennsylvania, United States

What year was Coeptis Therapeutics founded?

founded flag
Year Founded
2017
What does Coeptis Therapeutics specialise in?
/Drug Development /Pharmaceutical Research /Novel Therapies /Innovative Treatments /Medical Advancement /Quality Assurance

What are the products and/or services of Coeptis Therapeutics?

Overview of Coeptis Therapeutics offerings
Development of CD38-targeted autologous CAR-T cell therapy for multiple myeloma.
Advancing SNAP-CAR platform for generating universal CAR-T cells with enhanced safety and efficacy.
Development of G1T38, an oral CDK4/6 inhibitor for breast cancer treatment.
Commercial partnership for distributing novel oncology therapies in specific markets.

Who is in the executive team of Coeptis Therapeutics?

Coeptis Therapeutics leadership team
  • Mr. David  Mehalick
    Mr. David Mehalick
    Co-Founder, Chairman of the Board, CEO & President
  • Ms. Christine Elise Sheehy
    Ms. Christine Elise Sheehy
    Co-Founder and VP of Compliance & Corporate Secretary
  • Mr. Daniel Alexander Yerace
    Mr. Daniel Alexander Yerace
    Co-Founder, VP of Operations & Director
  • Mr. Brian  Cogley M.B.A.
    Mr. Brian Cogley M.B.A.
    Chief Financial Officer
  • Dr. Colleen  Delaney M.D., M.Sc.
    Dr. Colleen Delaney M.D., M.Sc.
    CSO & Chief Medical Officer